Ashni Acquires BioNexus

Ashni Acquires BioNexus

SALT LAKE CITY--Ashni Nutraceuticals, developer and marketer of nutraceuticalproducts, has announced the acquisition of BioNexus Genomics, developer ofpatent-pending genomic/proteomic/signal transduction technology, which is usedto develop functional foods and proprietary dietary supplements. The acquisitionwill provide Ashni with access to technology to use in the development of itsbotanical and nutritional formulations.

"With the addition of genomic, proteomic and signal transductiontechnologies, Ashni will standardize quality and discover patentable combinationproducts with proven synergistic effect," said Ashni chairman, presidentand chief executive officer, Dinesh Patel.